QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
- 16 November 2017SV NewsDDF attracts investment from NFL Players Association
- 3 November 2017Portfolio NewsDDF attracts $50 million investment from Bill Gates
- 24 October 2017Portfolio NewsDDF notes major collaboration between portfolio company Alector and AbbVie
- 6 July 2017Portfolio NewsDDF Invests in $20 Million in Series A Funding of Mitoconix Bio to Develop Neurodegenerative Disease Therapies
- 21 June 2017Portfolio NewsAdimab Provides Mid-Year Update on 2017 Partnership Activity
- 19 June 2017SV NewsDementia Discovery Fund Annual Update
- 1 June 2017Portfolio NewsBicycle Therapeutics Closes £40 Million ($52 Million) in Series B Financing to Advance Clinical Pipeline
- 3 May 2017Portfolio NewsDDF to Invest $5 Million in Cerevance to Seek New Treatments for Dementia
- 1 May 2017Portfolio NewsAligned Telehealth Names Dan Castillo President and COO
- 27 April 2017Portfolio NewsArsanis Completes $45.5 Million Series D Financing
- 11 April 2017SV NewsSV Health Investors Closes on New Fund Focused on Creating and Growing Companies That Advance Science and Transform Healthcare
- 10 April 2017SV NewsSV Life Sciences Changes Name to SV Health Investors to Better Reflect the Firm's Longstanding Strategy and Focus